WNT ligands in non-small cell lung cancer: from pathogenesis to clinical practice
Abstract Non-small cell lung cancer (NSCLC) is the malignant tumor with the highest morbidity and leading cause of death worldwide, whereas its pathogenesis has not been fully elucidated. Although mutations in some crucial genes in WNT pathways such as β-catenin and APC are not common in NSCLC, the...
| Main Authors: | , , , , , , , |
|---|---|
| Format: | Article |
| Language: | English |
| Published: |
Springer
2023-07-01
|
| Series: | Discover Oncology |
| Subjects: | |
| Online Access: | https://doi.org/10.1007/s12672-023-00739-7 |
| _version_ | 1797769465535922176 |
|---|---|
| author | Wanting Xue Lihong Cai Su Li Yujia Hou Yan-Dong Wang Dongbin Yang Yubing Xia Xiaobo Nie |
| author_facet | Wanting Xue Lihong Cai Su Li Yujia Hou Yan-Dong Wang Dongbin Yang Yubing Xia Xiaobo Nie |
| author_sort | Wanting Xue |
| collection | DOAJ |
| description | Abstract Non-small cell lung cancer (NSCLC) is the malignant tumor with the highest morbidity and leading cause of death worldwide, whereas its pathogenesis has not been fully elucidated. Although mutations in some crucial genes in WNT pathways such as β-catenin and APC are not common in NSCLC, the abnormal signal transduction of WNT pathways is still closely related to the occurrence and progression of NSCLC. WNT ligands (WNTs) are a class of secreted glycoproteins that activate WNT pathways through binding to their receptors and play important regulatory roles in embryonic development, cell differentiation, and tissue regeneration. Therefore, the abnormal expression or dysfunction of WNTs undoubtedly affects WNT pathways and thus participates in the pathogenesis of diseases. There are 19 members of human WNTs, WNT1, WNT2, WNT2b, WNT3, WNT3a, WNT4, WNT5a, WNT5b, WNT6, WNT7a, WNT7b, WNT8a, WNT8b, WNT9a, WNT9b, WNT10a, WNT10b, WNT11 and WNT16. The expression levels of WNTs, binding receptors, and activated WNT pathways are diverse in different tissue types, which endows the complexity of WNT pathways and multifarious biological effects. Although abundant studies have reported the role of WNTs in the pathogenesis of NSCLC, it still needs further study as therapeutic targets for lung cancer. This review will systematically summarize current research on human WNTs in NSCLC, from molecular pathogenesis to potential clinical practice. |
| first_indexed | 2024-03-12T21:09:24Z |
| format | Article |
| id | doaj.art-d46655e4622d435286edf4ce6b9a4832 |
| institution | Directory Open Access Journal |
| issn | 2730-6011 |
| language | English |
| last_indexed | 2024-03-12T21:09:24Z |
| publishDate | 2023-07-01 |
| publisher | Springer |
| record_format | Article |
| series | Discover Oncology |
| spelling | doaj.art-d46655e4622d435286edf4ce6b9a48322023-07-30T11:18:42ZengSpringerDiscover Oncology2730-60112023-07-0114111710.1007/s12672-023-00739-7WNT ligands in non-small cell lung cancer: from pathogenesis to clinical practiceWanting Xue0Lihong Cai1Su Li2Yujia Hou3Yan-Dong Wang4Dongbin Yang5Yubing Xia6Xiaobo Nie7Key Laboratory of Receptors-Mediated Gene Regulation and Drug Discovery, School of Basic Medical Sciences, Hebi Key Laboratory of Liver Disease, People’s Hospital of Hebi, Henan UniversityKaifeng Key Laboratory of Radiation Oncology, Kaifeng Cancer Hospital, Kaifeng UniversityKey Laboratory of Receptors-Mediated Gene Regulation and Drug Discovery, School of Basic Medical Sciences, Hebi Key Laboratory of Liver Disease, People’s Hospital of Hebi, Henan UniversityKey Laboratory of Receptors-Mediated Gene Regulation and Drug Discovery, School of Basic Medical Sciences, Hebi Key Laboratory of Liver Disease, People’s Hospital of Hebi, Henan UniversityState Key Laboratory of Chemical Resource Engineering, College of Life Science and Technology, Beijing University of Chemical TechnologyKey Laboratory of Receptors-Mediated Gene Regulation and Drug Discovery, School of Basic Medical Sciences, Hebi Key Laboratory of Liver Disease, People’s Hospital of Hebi, Henan UniversityKaifeng Key Laboratory of Radiation Oncology, Kaifeng Cancer Hospital, Kaifeng UniversityKey Laboratory of Receptors-Mediated Gene Regulation and Drug Discovery, School of Basic Medical Sciences, Hebi Key Laboratory of Liver Disease, People’s Hospital of Hebi, Henan UniversityAbstract Non-small cell lung cancer (NSCLC) is the malignant tumor with the highest morbidity and leading cause of death worldwide, whereas its pathogenesis has not been fully elucidated. Although mutations in some crucial genes in WNT pathways such as β-catenin and APC are not common in NSCLC, the abnormal signal transduction of WNT pathways is still closely related to the occurrence and progression of NSCLC. WNT ligands (WNTs) are a class of secreted glycoproteins that activate WNT pathways through binding to their receptors and play important regulatory roles in embryonic development, cell differentiation, and tissue regeneration. Therefore, the abnormal expression or dysfunction of WNTs undoubtedly affects WNT pathways and thus participates in the pathogenesis of diseases. There are 19 members of human WNTs, WNT1, WNT2, WNT2b, WNT3, WNT3a, WNT4, WNT5a, WNT5b, WNT6, WNT7a, WNT7b, WNT8a, WNT8b, WNT9a, WNT9b, WNT10a, WNT10b, WNT11 and WNT16. The expression levels of WNTs, binding receptors, and activated WNT pathways are diverse in different tissue types, which endows the complexity of WNT pathways and multifarious biological effects. Although abundant studies have reported the role of WNTs in the pathogenesis of NSCLC, it still needs further study as therapeutic targets for lung cancer. This review will systematically summarize current research on human WNTs in NSCLC, from molecular pathogenesis to potential clinical practice.https://doi.org/10.1007/s12672-023-00739-7WNT ligandsNon-small cell lung cancerWNT signaling pathwaysTherapeutic targets |
| spellingShingle | Wanting Xue Lihong Cai Su Li Yujia Hou Yan-Dong Wang Dongbin Yang Yubing Xia Xiaobo Nie WNT ligands in non-small cell lung cancer: from pathogenesis to clinical practice Discover Oncology WNT ligands Non-small cell lung cancer WNT signaling pathways Therapeutic targets |
| title | WNT ligands in non-small cell lung cancer: from pathogenesis to clinical practice |
| title_full | WNT ligands in non-small cell lung cancer: from pathogenesis to clinical practice |
| title_fullStr | WNT ligands in non-small cell lung cancer: from pathogenesis to clinical practice |
| title_full_unstemmed | WNT ligands in non-small cell lung cancer: from pathogenesis to clinical practice |
| title_short | WNT ligands in non-small cell lung cancer: from pathogenesis to clinical practice |
| title_sort | wnt ligands in non small cell lung cancer from pathogenesis to clinical practice |
| topic | WNT ligands Non-small cell lung cancer WNT signaling pathways Therapeutic targets |
| url | https://doi.org/10.1007/s12672-023-00739-7 |
| work_keys_str_mv | AT wantingxue wntligandsinnonsmallcelllungcancerfrompathogenesistoclinicalpractice AT lihongcai wntligandsinnonsmallcelllungcancerfrompathogenesistoclinicalpractice AT suli wntligandsinnonsmallcelllungcancerfrompathogenesistoclinicalpractice AT yujiahou wntligandsinnonsmallcelllungcancerfrompathogenesistoclinicalpractice AT yandongwang wntligandsinnonsmallcelllungcancerfrompathogenesistoclinicalpractice AT dongbinyang wntligandsinnonsmallcelllungcancerfrompathogenesistoclinicalpractice AT yubingxia wntligandsinnonsmallcelllungcancerfrompathogenesistoclinicalpractice AT xiaobonie wntligandsinnonsmallcelllungcancerfrompathogenesistoclinicalpractice |